Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 1

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 1
---
: You are cordially invited to attend a Special Meeting of Stockholders of Plus Therapeutics, Inc. (the “Special Meeting”) on [], 2025, commencing at [9:00 a.m. Eastern Time]. The Special Meeting will be a completely virtual meeting. The items of business for the meeting, as more fully described in the attached proxy statement, are: Proposal No. 1: To grant discretionary authority to our board of directors to (i) amend our Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to combine outstanding shares of our common stock, par value $0.001 per share (the “Common Stock”), into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-twenty five (1-for-25) to a maximum of a one-for-two hundred fifty (1-for-250), with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders; Proposal No. 2: To authorize, for purposes of complying with Listing Rule 5635(d) of The Nasdaq Stock Market LLC (“Nasdaq”), the issuance of Series A Warrants and Series B Warrants (each as defined in the accompanying Proxy Statement) and shares of Common Stock underlying the Warrants (as defined in the accompanying Proxy Statement) and certain provisions of the Warrants, issued in connection with an offering and sale of securities in a private placement of the Company that was consummated on March 4, 2025; Proposal No. 3: To amend the Certificate of Incorporation to increase the authorized shares of Common Stock from 100,000,000 shares to 2,000,000,000 shares; Proposal No. 4: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the extension of the term of the Company’s May 2024 Warrants (as defined in the accompanying Proxy Statement), issued in connection with an offering and sale of securities in a private placement of the Company that was consummated on May 9, 2024; and Proposal No. 5: To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of each of the preceding proposals if there are not sufficient votes at the Special Meeting to approve and adopt the